Winnow Wealth LLC Buys Shares of 24,204 Exelixis, Inc. $EXEL

Winnow Wealth LLC purchased a new position in Exelixis, Inc. (NASDAQ:EXEL) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 24,204 shares of the biotechnology company’s stock, valued at approximately $1,017,000.

Other large investors have also made changes to their positions in the company. Arizona State Retirement System increased its position in Exelixis by 4.3% during the 3rd quarter. Arizona State Retirement System now owns 76,652 shares of the biotechnology company’s stock worth $3,166,000 after purchasing an additional 3,172 shares in the last quarter. Impact Partnership Wealth LLC boosted its stake in shares of Exelixis by 17.3% during the 3rd quarter. Impact Partnership Wealth LLC now owns 9,788 shares of the biotechnology company’s stock worth $404,000 after purchasing an additional 1,443 shares during the last quarter. Foundations Investment Advisors LLC acquired a new stake in shares of Exelixis during the 3rd quarter worth about $322,000. Ruffer LLP grew its holdings in shares of Exelixis by 7.1% during the third quarter. Ruffer LLP now owns 81,696 shares of the biotechnology company’s stock worth $3,374,000 after buying an additional 5,386 shares in the last quarter. Finally, New York State Common Retirement Fund raised its position in shares of Exelixis by 2.3% in the third quarter. New York State Common Retirement Fund now owns 145,147 shares of the biotechnology company’s stock valued at $5,995,000 after buying an additional 3,200 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

EXEL has been the topic of a number of analyst reports. Citigroup lowered shares of Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. Truist Financial set a $51.00 price target on Exelixis in a research note on Wednesday, January 14th. Guggenheim downgraded Exelixis from a “buy” rating to a “neutral” rating in a research report on Monday, November 3rd. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $45.00 target price on shares of Exelixis in a research note on Tuesday, October 21st. Finally, Oppenheimer reissued a “market perform” rating and issued a $36.00 price target on shares of Exelixis in a research note on Wednesday, November 5th. Eleven research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Exelixis has a consensus rating of “Hold” and an average price target of $45.95.

Exelixis Trading Down 2.2%

Shares of Exelixis stock opened at $41.36 on Friday. The business’s fifty day moving average price is $43.76 and its 200 day moving average price is $41.06. Exelixis, Inc. has a twelve month low of $32.38 and a twelve month high of $49.62. The stock has a market capitalization of $11.09 billion, a P/E ratio of 17.45, a PEG ratio of 0.76 and a beta of 0.40.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. The company had revenue of $597.76 million for the quarter, compared to the consensus estimate of $590.04 million. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The company’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period last year, the business posted $0.47 EPS. As a group, sell-side analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director Mary C. Beckerle sold 24,622 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the completion of the sale, the director directly owned 21,380 shares in the company, valued at $896,463.40. The trade was a 53.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Dana Aftab sold 48,383 shares of the stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $42.50, for a total transaction of $2,056,277.50. Following the completion of the sale, the executive vice president directly owned 664,778 shares of the company’s stock, valued at $28,253,065. The trade was a 6.78% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 245,235 shares of company stock valued at $10,490,600. 2.82% of the stock is currently owned by corporate insiders.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.